on PolyPeptide Group
Samsung Biologics' Tender Offer for PolyPeptide: Interim Results Released
Samsung Biologics, via its subsidiary Samsung Peptide, announced the interim results of its public tender offer for PolyPeptide Group's shares. The offer concluded on October 12, 2026. Samsung Peptide now holds 87.92% of PolyPeptide's shares, with 87.59% tendered during the offer.
The offer's conditions regarding minimum acceptance and absence of adverse effects were met. Samsung Peptide plans a squeeze-out of remaining shareholders and seeks delisting from SIX Swiss Exchange. The additional acceptance period runs from October 19 to 30, 2026.
Regulatory approval is pending. Completion is expected by late 2026 or early 2027, with the settlement delayed as specified in the offer documentation. An extraordinary general meeting is scheduled for October 26 to address certain conditions.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all PolyPeptide Group news